Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

by · The Markets Daily

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note issued to investors on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Get Our Latest Analysis on Lipocine

Lipocine Stock Performance

Lipocine stock opened at $4.37 on Friday. The stock has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $5.02. The stock has a market capitalization of $23.38 million, a P/E ratio of -5.75 and a beta of 1.23. Lipocine has a 52 week low of $3.20 and a 52 week high of $11.79.

Lipocine (NASDAQ:LPCN – Get Free Report) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. Research analysts forecast that Lipocine will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC boosted its position in Lipocine Inc. (NASDAQ:LPCN – Free Report) by 21.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. 9.11% of the stock is currently owned by institutional investors and hedge funds.

About Lipocine

(Get Free Report)

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Recommended Stories